• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . An epitope-based peptide vaccine targeting influenza a elicits robust immune responses and induces protection in a mouse model

tetano

Editor, Senior Moderator
Sci Rep


. 2026 Jul 3.
doi: 10.1038/s41598-026-60696-3. Online ahead of print.
An epitope-based peptide vaccine targeting influenza a elicits robust immune responses and induces protection in a mouse model

Bandar Alosaimi[SUP] 1 [/SUP], Halah Z Al-Rawi[SUP] 1 [/SUP], Reham M Alahmadi[SUP] 2 [/SUP], Samia T Al-Shouli[SUP] 3 [/SUP], Jehad Alzahrani[SUP] 4 [/SUP], Roua Alsubki[SUP] 5 [/SUP], Maaweya E Awadalla[SUP] 6 [/SUP]


Affiliations
Abstract

Influenza A viruses remain a major global public health threat due to their high mutation rates, antigenic drift, and periodic antigenic shift, which collectively undermine the effectiveness of seasonal vaccines. Conventional influenza vaccines necessitate frequent reformulation and often result in suboptimal protection. Epitope-based vaccine strategies that focus immune responses toward conserved viral regions represent a promising approach for inducing broader and durable immunity. In this study, reverse vaccinology and immunoinformatics-guided approaches were used to design multi-epitope vaccine constructs derived from conserved regions of Influenza A H3N2 and H1N1 proteins, including hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), and matrix proteins (M1 and M2). BALB/c mice were immunized intramuscularly and evaluated for humoral and cellular immune responses. Serum IgG levels were measured by ELISA, while functional antibodies were assessed using hemagglutination inhibition (HAI) assays. Cellular immune responses were evaluated using ELISPOT assays for IFN-γ and TNF-α secretion. Protective efficacy was assessed through homologous viral challenge with H3N2 or H1N1 strains, followed by survival analysis and lung histopathological examination. Immunization with H3N2- and H1N1-derived epitopes elicited robust specific IgG responses and induced functional HAI antibodies. Notably, H3N2-derived epitopes generated higher HAI titers, consistent with enhanced humoral immunogenicity. Vaccinated mice demonstrated strong cellular immune responses, characterized by significantly elevated IFN-γ-producing CD8⁺ T cells compared with mock-immunized controls. Upon viral challenge, all vaccinated mice exhibited 100% survival against H3N2 or H1N1 infection, whereas mock-immunized mice experienced 100% mortality. Histopathological analysis revealed protective immunopathological profiles and preserved alveolar architecture. The protective efficacy of the multi-epitope vaccination was comparable to that of the seasonal quadrivalent influenza vaccine. This study demonstrates that multi-epitope vaccines derived from conserved Influenza A proteins can induce coordinated humoral and cellular immune responses and confer robust protection against H3N2 and H1N1 viral challenge in a mouse model. This suggests support for peptide-based vaccination as an alternative method to conventional strain-matched vaccines, which reduce vaccine effectiveness or universal influenza vaccine development.


 
Back
Top